Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ATRC

Atricure Inc

Feb 13 • 04:00PM ET

32.65

+0.85 2.67 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Feb 11, 11:02 AMJPMorgan downgrade from overweight to neutral triggered sharp gap down and 15% intraday decline.

Peers: BSX ABT MDT EW ISRG BIO JNJ IART LMAT ZBH

| Held by: VTI VB IWM VBK VXF IWO VTWO FESM SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	3.68%	Shs Outstand	49.71M	Perf Week	-12.02%
Market Cap	1.62B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-1.67%	Shs Float	47.89M	Perf Month	-12.63%
Enterprise Value	1.56B	PEG	-	EPS next Q	-0.09	Inst Own	98.43%	Short Float	5.24%	Perf Quarter	-1.24%
Income	-28.77M	P/S	3.13	EPS this Y	61.73%	Inst Trans	-0.58%	Short Ratio	4.50	Perf Half Y	-7.79%
Sales	518.30M	P/B	3.41	EPS next Y	97.03%	ROA	-4.60%	Short Interest	2.51M	Perf YTD	-17.47%
Book/sh	9.59	P/C	10.98	EPS next 5Y	-	ROE	-6.11%	52W High	43.18 -24.39%	Perf Year	-17.53%
Cash/sh	2.97	P/FCF	50.84	EPS past 3/5Y	- -0.33%	ROIC	-5.17%	52W Low	28.29 15.41%	Perf 3Y	-24.30%
Dividend Est.	-	EV/EBITDA	144.42	Sales past 3/5Y	19.26% 15.05%	Gross Margin	74.28%	Volatility	6.37% 5.04%	Perf 5Y	-50.98%
Dividend TTM	-	EV/Sales	3.01	EPS Y/Y TTM	26.94%	Oper. Margin	-1.83%	ATR (14)	2.00	Perf 10Y	97.52%
Dividend Ex-Date	-	Quick Ratio	2.85	Sales Y/Y TTM	15.80%	Profit Margin	-5.55%	RSI (14)	34.96	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	3.87	EPS Q/Q	96.64%	SMA20	-11.94%	Beta	1.43	Target Price	51.44
Payout	-	Debt/Eq	0.17	Sales Q/Q	15.84%	SMA50	-16.19%	Rel Volume	2.93	Prev Close	31.80
Employees	1300	LT Debt/Eq	0.17	Earnings	Feb 17 AMC	SMA200	-7.45%	Avg Volume	558.19K	Price	32.65
IPO	Aug 05, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	91.06% 2.29%	Trades		Volume	1,636,197	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-26	Downgrade	JP Morgan	Overweight → Neutral	$36
Dec-17-24	Resumed	JP Morgan	Overweight	$40
Apr-23-24	Upgrade	Oppenheimer	Perform → Outperform	$32
Oct-23-23	Initiated	JMP Securities	Mkt Outperform	$60
Sep-29-23	Initiated	UBS	Buy	$56
Aug-05-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Reiterated	Needham	Buy	$53 → $63
Nov-06-20	Reiterated	Needham	Buy	$63 → $53
Apr-07-20	Initiated	Oppenheimer	Outperform	$45
Feb-06-20	Initiated	BTIG Research	Buy	$42
Jan-24-20	Reiterated	Needham	Buy	$39 → $48
Aug-13-19	Downgrade	Northland Capital	Outperform → Market Perform	$30
Apr-12-19	Initiated	JP Morgan	Overweight	$37
Oct-04-18	Reiterated	Needham	Buy	$36 → $39
Aug-02-18	Reiterated	Stifel	Buy	$32 → $34
Aug-02-18	Reiterated	Needham	Buy	$32 → $36
Jun-18-18	Reiterated	Needham	Buy	$26 → $32
Apr-27-18	Reiterated	Needham	Buy	$23 → $26
Jan-16-18	Reiterated	Needham	Buy	$25 → $23
Nov-02-17	Reiterated	Needham	Buy	$26 → $25

Show Previous Ratings

Feb-12-26 12:57PM	Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care (Zacks)
Feb-11-26 10:00AM	Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth (Zacks) -13.11%
Feb-10-26 12:20PM	GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency (Zacks)
10:00AM	Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-09-26 10:40AM	GEHC Strengthens AI Fetal Ultrasound via Diagnoly Collaboration (Zacks)
10:48AM	Loading…
Feb-06-26 10:48AM	MCK Q3 Earnings & Sales Top Estimates, 2026 View Up (Zacks)
Feb-05-26 12:33PM	DXCM Upgrades Stelo With AI-Powered Smart Meal Logging Features (Zacks)
10:27AM	CAH Q2 Earnings Beat Estimates, '26 EPS View Up, Stock Gains (Zacks)
Feb-04-26 12:57PM	Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test (Zacks)
11:59AM	Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves (Zacks)
11:03AM	GE HealthCare Q4 Earnings and Revenues Beat Estimates, Net Margin Falls (Zacks)
Feb-03-26 01:13PM	GEHC Wins FDA Clearance & CE Mark for Allia Moveo, Marks Global Debut (Zacks)
Feb-02-26 09:49AM	Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates (Zacks)
Jan-30-26 01:34PM	GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test (Zacks)
10:25AM	SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption (Zacks)
01:32PM	Loading…
Jan-29-26 01:32PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
Jan-28-26 11:26AM	QT Imaging & Olea Medical Partner to Enhance Cloud Imaging Platform (Zacks)
Jan-27-26 12:07PM	ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures (Zacks)
08:00AM	AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
07:53AM	CLPT Gets EU MDR Certification for ClearPoint Navigation Software (Zacks)
Jan-23-26 04:14AM	The Zacks Analyst Blog Highlights AtriCure, REV Group, Oceaneering International and Analog Devices (Zacks)
Jan-22-26 09:32AM	4 High-Efficiency Stocks Poised to Deliver Superior Returns (Zacks)
Jan-20-26 11:04AM	Organon Secures FDA Approval Extending NEXPLANON Use to Five Years (Zacks)
11:00AM	Here's Why You Should Retain CLOV Stock in Your Portfolio for Now (Zacks)
Jan-19-26 12:40PM	Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology (Zacks)
Jan-16-26 12:46PM	Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results (Zacks) -5.79%
12:42PM	DexCom Stock Declines Following Strong Preliminary Q4 Results (Zacks)
09:34AM	Here's Why You Should Hold DexCom Stock in Your Portfolio for Now (Zacks)
Jan-15-26 12:09PM	CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026 (Zacks) +10.94%
09:36AM	Loading…
09:36AM	Reasons to Add Fresenius Medical Stock to Your Portfolio Now (Zacks)
Jan-14-26 06:24PM	AtriCure CEO Touts $10B AFib and Pain Market, Raises EBITDA Outlook at JPMorgan Conference (MarketBeat)
11:05AM	KMTS, Biobeat Partner to Expand Diagnostic Insight in Cardiac Recovery (Zacks)
Jan-12-26 10:21AM	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 (Business Wire) -9.21%
Jan-09-26 09:15AM	AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out? (Zacks)
Jan-06-26 11:39AM	OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device (Zacks)
Dec-29-25 10:57AM	Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA (Zacks)
Dec-24-25 09:40AM	Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-22-25 06:05AM	Analysts See an Over 26% Upside in AtriCure (ATRC) (Insider Monkey)
Dec-19-25 12:00PM	AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know (Zacks)
Dec-17-25 08:00AM	AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference (Business Wire)
Dec-15-25 10:39AM	Abbott Gains From Lingo CGM's Expansion on Android Platform (Zacks)
Dec-12-25 10:30AM	ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform (Zacks)
10:02AM	CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution (Zacks)
Dec-11-25 08:00AM	AtriCure Announces the First Patients Treated with Novel Dual Energy Platform (Business Wire)
Dec-08-25 09:40AM	Are Medical Stocks Lagging AtriCure (ATRC) This Year? (Zacks)
Nov-25-25 09:55AM	Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade (Zacks)
Nov-20-25 09:40AM	Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 08:00AM	AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-07-25 09:35AM	AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-06-25 02:16AM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised) (Zacks)
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-29-25 05:30PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Zacks)
05:10PM	AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:06PM	AtriCure: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 (Business Wire)
Oct-28-25 09:46AM	AtriCure Inc (ATRC) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial (Business Wire)
Oct-27-25 08:00AM	AtriCure to Participate in Upcoming Investor Conferences (Business Wire)
Oct-08-25 08:00AM	AtriCure to Announce Third Quarter 2025 Financial Results (Business Wire)
Oct-03-25 05:54AM	Medtronic wins CE mark for Penditure LAA exclusion device (MedTech Dive)
Sep-09-25 08:08AM	Do You Believe in the Upside Potential of Atricure (ATRC)? (Insider Monkey)
08:00AM	AtriCure Announces the Launch of the cryoXT Device for Post-Operative Pain Management Following Amputation (Business Wire)
Aug-20-25 08:00AM	AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference (Business Wire)
Jul-30-25 03:16AM	AtriCure Inc (ATRC) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Milestones (GuruFocus.com) +10.72%
Jul-29-25 05:30PM	AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:08PM	AtriCure: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure ReportsSecondQuarter2025 Financial Results; Raises Financial Outlook for 2025 (Business Wire)
Jul-28-25 08:00AM	AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire) +5.46%
Jul-17-25 08:40AM	Abbott (ABT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-15-25 08:00AM	AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention (Business Wire)
Jul-08-25 08:00AM	AtriCure to Announce Second Quarter 2025 Financial Results (Business Wire)
Jun-30-25 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-12-25 09:40AM	Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? (Zacks)
May-27-25 09:40AM	Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-23-25 08:00AM	AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-15-25 09:55AM	Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? (Zacks)
Apr-30-25 08:07AM	Q1 2025 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents) -13.68%
03:15AM	AtriCure Inc (ATRC) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 09:34PM	AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:10PM	AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	AtriCure: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-10-25 11:37AM	LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock? (Zacks)
08:00AM	AtriCure Announces First Use of the AtriClip PRO-Mini Device (Business Wire)
Apr-09-25 08:10AM	Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates (Zacks) +8.13%
Apr-08-25 12:18PM	AtriCure Drops 25%: Bargain Or Caution Sign? (Seeking Alpha)
08:00AM	AtriCure to Announce First Quarter 2025 Financial Results (Business Wire)
Mar-12-25 08:00AM	AtriCure to Host Analyst & Investor Day on March 26, 2025 (Business Wire)
Feb-13-25 12:00PM	AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know (Zacks) -6.54%
10:29AM	Q4 2024 AtriCure Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-12-25 05:30PM	Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings (Zacks)
05:15PM	AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:38PM	AtriCure: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results (Business Wire)
Feb-11-25 09:15AM	Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-25 10:00AM	Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know (Zacks)

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WEHRWEIN SVEN	Director	Nov 24 '25	Option Exercise	19.95	5,033	100,408	39,407	Nov 26 04:43 PM
WEHRWEIN SVEN	Director	Nov 25 '25	Option Exercise	19.95	4,967	99,092	39,341	Nov 26 04:43 PM
WEHRWEIN SVEN	Director	Nov 25 '25	Sale	38.00	4,967	188,746	34,374	Nov 26 04:43 PM
WEHRWEIN SVEN	Director	Nov 24 '25	Sale	37.32	5,033	187,832	34,374	Nov 26 04:43 PM
Noznesky Justin J	Chief Mktg & Strategy Officer	Nov 26 '25	Sale	37.29	5,166	192,640	78,798	Nov 26 04:41 PM
Noznesky Justin J	Officer	Nov 26 '25	Proposed Sale	37.29	5,166	192,642		Nov 26 11:48 AM
SVEN WEHRWEIN	Director	Nov 25 '25	Proposed Sale	38.00	4,967	188,746		Nov 25 04:06 PM
Yuen Maggie	Director	Nov 21 '25	Sale	35.72	3,000	107,160	11,371	Nov 25 09:01 AM
SVEN WEHRWEIN	Director	Nov 24 '25	Proposed Sale	37.32	5,033	187,854		Nov 24 05:41 PM
MAGGIE YUEN	Director	Nov 21 '25	Proposed Sale	35.72	3,000	107,158		Nov 21 05:53 PM
Noznesky Justin J	Chief Mktg & Strategy Officer	Sep 12 '25	Sale	36.30	3,000	108,900	83,964	Sep 16 08:45 AM
Noznesky Justin J	Officer	Sep 12 '25	Proposed Sale	36.30	3,000	108,891		Sep 12 02:17 PM
WEHRWEIN SVEN	Director	Aug 22 '25	Option Exercise	19.95	5,000	99,750	39,374	Aug 26 08:27 AM
WEHRWEIN SVEN	Director	Aug 22 '25	Sale	37.00	5,000	185,000	34,374	Aug 26 08:27 AM
SVEN WEHRWEIN	Director	Aug 22 '25	Proposed Sale	37.00	5,000	185,000		Aug 22 04:01 PM
WEHRWEIN SVEN	Director	Aug 19 '25	Option Exercise	19.95	5,000	99,750	39,374	Aug 21 09:04 AM
WEHRWEIN SVEN	Director	Aug 19 '25	Sale	36.00	5,000	180,000	34,374	Aug 21 09:04 AM
SVEN WEHRWEIN	Director	Aug 19 '25	Proposed Sale	36.00	5,000	180,000		Aug 19 04:12 PM
GROVES REGINA E	Director	Aug 06 '25	Sale	36.82	2,452	90,283	33,715	Aug 08 09:12 AM
Doraiswamy Vinayak	Chief Scientific Officer	Aug 05 '25	Sale	36.58	2,500	91,450	71,872	Aug 07 08:45 AM
GROVES REGINA E	Director	Aug 06 '25	Proposed Sale	36.83	2,452	90,307		Aug 06 10:38 AM
VINAYAK DORAISWAMY	Officer	Aug 05 '25	Proposed Sale	36.58	2,500	91,442		Aug 05 04:08 PM
Doraiswamy Vinayak	Chief Scientific Officer	May 28 '25	Sale	33.44	2,500	83,600	73,550	May 30 04:21 PM
VINAYAK DORAISWAMY	Officer	May 28 '25	Proposed Sale	33.44	2,500	83,600		May 28 04:02 PM
WHITE ROBERT S.	Director	May 05 '25	Option Exercise	22.62	10,000	226,200	106,773	May 07 08:25 AM
Prange Karen	Director	Mar 05 '25	Sale	38.12	6,100	232,532	17,828	Mar 07 08:21 AM
Prange Karen	Director	Mar 05 '25	Proposed Sale	38.04	6,100	232,044		Mar 05 10:02 AM

Open in Screener

FLGT

Fulgent Genetics Inc

Feb 13 • 04:00PM ET

23.43

+0.46 2.00 %

Healthcare • Diagnostics & Research • USA • NASD

FLGT Fulgent Genetics Inc daily Stock Chart

Peers: ILMN QGEN EXAS GH CDNA TXG ONC VCYT MYGN OMIC

| Held by: VTI IWM VXF FNDA IWN IBB VTWO DFAS SCHA DFAC

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	35.33%	Shs Outstand	30.85M	Perf Week	-0.04%
Market Cap	724.28M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	-0.19%	Shs Float	19.99M	Perf Month	-16.23%
Enterprise Value	351.34M	PEG	-	EPS next Q	0.03	Inst Own	55.00%	Short Float	8.45%	Perf Quarter	-19.43%
Income	-42.98M	P/S	2.30	EPS this Y	-42.88%	Inst Trans	3.33%	Short Ratio	7.11	Perf Half Y	7.77%
Sales	315.55M	P/B	0.64	EPS next Y	-214.35%	ROA	-3.51%	Short Interest	1.69M	Perf YTD	-10.81%
Book/sh	36.49	P/C	1.93	EPS next 5Y	-	ROE	-3.80%	52W High	31.04 -24.52%	Perf Year	38.97%
Cash/sh	12.16	P/FCF	-	EPS past 3/5Y	- -129.89%	ROIC	-3.80%	52W Low	14.57 60.81%	Perf 3Y	-29.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.15% 54.19%	Gross Margin	38.71%	Volatility	3.16% 3.18%	Perf 5Y	-85.46%
Dividend TTM	-	EV/Sales	1.11	EPS Y/Y TTM	74.64%	Oper. Margin	-22.50%	ATR (14)	0.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	13.60%	Profit Margin	-13.62%	RSI (14)	28.90	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.01	EPS Q/Q	55.38%	SMA20	-8.75%	Beta	0.89	Target Price	33.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	17.18%	SMA50	-12.17%	Rel Volume	0.69	Prev Close	22.97
Employees	1313	LT Debt/Eq	0.01	Earnings	Feb 27 BMO	SMA200	1.58%	Avg Volume	237.50K	Price	23.43
IPO	Sep 29, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	162.44% 3.24%	Trades		Volume	163,626	Change	2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-25	Upgrade	UBS	Neutral → Buy	$30
Dec-07-23	Initiated	UBS	Neutral	$35
Dec-08-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $40
Nov-18-22	Initiated	Raymond James	Outperform	$45
Aug-25-22	Initiated	Credit Suisse	Outperform	$65
Feb-04-22	Resumed	Piper Sandler	Overweight	$80
Aug-05-21	Resumed	Credit Suisse	Underperform	$55
Jan-08-21	Downgrade	Credit Suisse	Neutral → Underperform	$42 → $40
Nov-24-20	Downgrade	BTIG Research	Buy → Neutral
Aug-20-20	Initiated	Oppenheimer	Outperform	$75
May-29-20	Initiated	BTIG Research	Buy	$20
Nov-05-19	Upgrade	Piper Jaffray	Neutral → Overweight
Mar-01-18	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Feb-12-26 07:30AM	Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026 (Business Wire)
Feb-05-26 05:15PM	Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates (Zacks) -7.13%
Jan-12-26 05:55AM	New Strong Buy Stocks for January 12th (Zacks)
Dec-23-25 12:35PM	FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform (Zacks)
02:12AM	Fulgent Genetics to buy Bako Diagnostics assets and StrataDx (Medical Device Network)
04:10PM	Loading…
Dec-22-25 04:10PM	Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx (Business Wire)
Nov-08-25 02:05AM	Fulgent Genetics Inc (FLGT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Upward ... (GuruFocus.com)
Nov-07-25 04:05PM	Fulgent to Participate in Upcoming Conferences (Business Wire) +18.15%
08:20AM	Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:05AM	Fulgent Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-06-25 06:35PM	Evolent Health (EVH) Misses Q3 Earnings Estimates (Zacks)
Oct-21-25 07:05AM	Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength? (Zacks)
Oct-20-25 06:00AM	Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference (Business Wire) +5.11%
Oct-16-25 07:00AM	Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025 (Business Wire)
Sep-11-25 07:00PM	Fulgent Genetics: A Risky Bet or a Hidden Gem? (Motley Fool)
03:07AM	Loading…
Aug-02-25 03:07AM	Fulgent Genetics Inc (FLGT) Q2 2025 Earnings Call Highlights: Strong Core Revenue Growth Amid ... (GuruFocus.com)
Aug-01-25 04:26PM	Why Fulgent Genetics Stock Was Crushing It on Friday (Motley Fool) +7.86%
08:10AM	Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:00AM	Fulgent Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-17-25 07:00AM	Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM (Business Wire)
Jul-10-25 04:05PM	Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025 (Business Wire)
May-19-25 08:11AM	Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc (PR Newswire)
May-03-25 03:03AM	Fulgent Genetics Inc (FLGT) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
May-02-25 11:35PM	Q1 2025 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) +19.07%
12:27PM	Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	Fulgent Reports First Quarter 2025 Financial Results (Business Wire)
Apr-21-25 04:37PM	Fulgent Genetics Inc (FLGT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Apr-10-25 04:05PM	Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025 (Business Wire) +9.64%
Apr-04-25 02:30PM	Stock Picks From Seeking Alpha's March 2025 New Analysts (Seeking Alpha)
08:01AM	Loading…
Mar-24-25 08:01AM	Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Mar-20-25 05:46AM	Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy (SeekingAlpha)
Mar-07-25 06:19PM	DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) -9.20%
Feb-28-25 11:30PM	Q4 2024 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:05PM	Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 (Business Wire)
Dec-09-24 09:55AM	Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know (Zacks)
Nov-22-24 12:00PM	All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy (Zacks) +5.43%
Nov-19-24 07:16PM	Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-09-24 07:31AM	Fulgent Genetics Reports Strong Q3 2024 Results (TipRanks)
02:05AM	Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline (GuruFocus.com)
Nov-08-24 08:15AM	Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) -11.76%
07:00AM	Fulgent Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 08:00AM	Fulgent to Participate in Upcoming Conferences (Business Wire)
Nov-01-24 08:08AM	Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Oct-31-24 08:00AM	Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1 (Business Wire) +5.82%
Oct-17-24 04:05PM	Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 (Business Wire)
Aug-13-24 12:00PM	Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22% (Zacks)
Aug-02-24 08:15AM	Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates (Zacks) +6.32%
07:00AM	Fulgent Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-18-24 04:36AM	Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks) -5.53%
Jul-11-24 04:05PM	Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024 (Business Wire) +5.41%
Jun-10-24 01:00AM	Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing (GlobeNewswire)
Jun-03-24 08:00AM	Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer (Business Wire)
May-24-24 08:00AM	Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting (Business Wire)
May-15-24 04:21AM	Moffitt and Fulgent Pharma partner on personalised cancer therapies (Pharmaceutical Technology)
May-14-24 04:05PM	Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics (Business Wire)
09:00AM	Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain (PR Newswire)
May-04-24 09:15AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Fulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ... (GuruFocus.com)
May-03-24 10:46PM	Q1 2024 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	FLGT Stock Earnings: Fulgent Genetics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:34AM	Fulgent Genetics Inc (FLGT) Q1 2024 Earnings: Misses Analyst Forecasts with Wider Losses (GuruFocus.com)
08:15AM	Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Fulgent Reports First Quarter 2024 Financial Results (Business Wire)
Apr-11-24 04:05PM	Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 (Business Wire)
Feb-29-24 09:31AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 10:18PM	Q4 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) -8.14%
07:35AM	Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023 (GuruFocus.com)
07:00AM	Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-13-24 08:00AM	Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024 (Business Wire)
Feb-09-24 08:31AM	Cord Blood Registry (CBR) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing (PR Newswire)
Nov-25-23 09:45AM	The 3 Best Digital Health Stocks for Personalized Medicine (InvestorPlace)
Nov-14-23 04:30PM	Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-05-23 09:02AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 10:26PM	Q3 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) +13.24%
04:05PM	Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting (Business Wire)
08:52AM	Fulgent Genetics Inc (FLGT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:45AM	Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Fulgent Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-25-23 08:00AM	Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting (Business Wire)
Oct-18-23 09:44AM	Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength? (Zacks)
Oct-17-23 08:00AM	Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023 (Business Wire)
Aug-05-23 08:56AM	Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 10:08PM	Q2 2023 Fulgent Genetics Inc Earnings Call (Thomson Reuters StreetEvents) -12.82%
08:15AM	Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Fulgent Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-24-23 04:05PM	Exagen Inc. Appoints Paul Kim to Board of Directors (GlobeNewswire)
Jul-18-23 08:00AM	Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023 (Business Wire)
Jun-21-23 08:00PM	FLGT: Lowering target price to $29.00 (Argus Research)
Jun-14-23 11:40AM	10 DNA Stocks Billionaires Are Loading Up On (Insider Monkey)
Jun-06-23 07:45AM	Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist (Motley Fool)
Jun-05-23 08:30AM	Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers (Business Wire)
May-23-23 09:53AM	Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics (Motley Fool)
08:20AM	2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years (Motley Fool)
May-18-23 04:05PM	Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting (Business Wire) +6.13%
May-08-23 11:15AM	3 Cash-Rich Biotechs in a Market That's Tough on the Debt Burdened (TheStreet.com)

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xie Jian	President and COO	Dec 02 '25	Sale	28.33	1,140	32,298	336,749	Dec 03 05:04 PM
Gao Hanlin	Chief Scientific Officer	Dec 02 '25	Sale	28.33	1,075	30,457	952,890	Dec 03 05:04 PM
Xie Jian	President and COO	Nov 28 '25	Sale	29.57	1,198	35,424	337,889	Dec 01 09:14 PM
Gao Hanlin	Chief Scientific Officer	Nov 28 '25	Sale	29.57	943	27,884	953,965	Dec 01 09:14 PM
Gao Hanlin	Officer	Dec 02 '25	Proposed Sale	28.52	1,070	30,516		Dec 01 09:13 PM
Xie Jian	Officer	Dec 02 '25	Proposed Sale	28.52	1,135	32,370		Dec 01 09:12 PM
Xie Jian	Officer	Nov 28 '25	Proposed Sale	30.15	1,198	36,120		Nov 26 08:26 PM
Gao Hanlin	Officer	Nov 28 '25	Proposed Sale	30.15	943	28,431		Nov 26 08:24 PM
Xie Jian	President and COO	Nov 24 '25	Sale	30.47	681	20,752	339,087	Nov 25 04:30 PM
Gao Hanlin	Chief Scientific Officer	Nov 24 '25	Sale	30.47	535	16,303	954,908	Nov 25 04:30 PM
Xie Jian	Officer	Nov 24 '25	Proposed Sale	30.47	681	20,752		Nov 24 06:37 PM
Gao Hanlin	Officer	Nov 24 '25	Proposed Sale	30.47	535	16,303		Nov 24 06:36 PM
Xie Jian	President and COO	Nov 19 '25	Sale	29.10	10,000	290,983	349,768	Nov 21 04:30 PM
Xie Jian	Officer	Nov 19 '25	Proposed Sale	29.10	10,000	290,983		Nov 19 08:03 PM
Gao Hanlin	Chief Scientific Officer	Sep 03 '25	Sale	22.03	1,063	23,414	957,085	Sep 03 05:33 PM
Xie Jian	President and COO	Sep 03 '25	Sale	22.03	1,128	24,846	364,121	Sep 03 05:33 PM
Xie Jian	Officer	Sep 03 '25	Proposed Sale	22.03	1,128	24,846		Sep 03 05:29 PM
Gao Hanlin	Officer	Sep 03 '25	Proposed Sale	22.03	1,063	23,414		Sep 03 05:29 PM
Xie Jian	President and COO	Aug 27 '25	Sale	21.48	1,199	25,760	365,249	Aug 28 06:55 PM
Gao Hanlin	Chief Scientific Officer	Aug 27 '25	Sale	21.48	943	20,260	958,148	Aug 28 06:55 PM
Xie Jian	Officer	Aug 27 '25	Proposed Sale	21.48	1,199	25,760		Aug 27 07:49 PM
Gao Hanlin	Officer	Aug 27 '25	Proposed Sale	21.48	943	20,260		Aug 27 07:47 PM
Xie Jian	President and COO	Aug 25 '25	Sale	21.50	696	14,965	366,448	Aug 26 07:13 PM
Gao Hanlin	Chief Scientific Officer	Aug 25 '25	Sale	21.50	548	11,783	959,091	Aug 26 07:10 PM
Xie Jian	Officer	Aug 25 '25	Proposed Sale	21.50	696	14,965		Aug 25 08:24 PM
Gao Hanlin	Chief Scientific Officer	Jun 02 '25	Sale	20.29	754	15,299	961,281	Jun 03 04:47 PM
Xie Jian	President and COO	Jun 02 '25	Sale	20.29	1,135	23,030	371,496	Jun 03 04:46 PM
Xie Jian	Officer	Jun 02 '25	Proposed Sale	20.29	1,135	23,030		Jun 02 04:49 PM
Xie Jian	President and COO	May 27 '25	Sale	20.54	1,873	38,468	372,631	May 28 04:17 PM
Gao Hanlin	Chief Scientific Officer	May 27 '25	Sale	20.54	1,039	21,339	962,035	May 28 04:16 PM
Kim Paul	CFO and Treasurer	Mar 05 '25	Buy	15.96	100,000	1,596,470	348,282	Mar 05 06:47 PM

ATRC

Atricure Inc

FLGT

Fulgent Genetics Inc

Upgrade your FINVIZ experience